Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin.
Olafsson S, Rodriguez E, Lawson ARJ, Abascal F, Huber AR, Suembuel M, Jones PH, Gerdes S, Martincorena I, Weidinger S, Campbell PJ, Anderson CA. Olafsson S, et al. Among authors: weidinger s. Nat Genet. 2023 Nov;55(11):1892-1900. doi: 10.1038/s41588-023-01545-1. Epub 2023 Oct 26. Nat Genet. 2023. PMID: 37884686 Free PMC article.
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis.
Hartmann J, Moitinho-Silva L, Sander N, Harder I, Häsler R, Rodriguez E, Haufe E, Kleinheinz A, Abraham S, Heratizadeh A, Weisshaar E, Schäkel K, Handrick C, Augustin M, Wollenberg A, Staubach-Renz P, Ertner K, Sticherling M, Schwarz B, Quist S, Wiemers F, Schenck F, Wildberger J, Tittmann L, Lieb W, Schmitt J, Werfel T, Weidinger S; TREATgermany Study Group. Hartmann J, et al. Among authors: weidinger s. Allergy. 2023 Aug;78(8):2290-2300. doi: 10.1111/all.15742. Epub 2023 Apr 18. Allergy. 2023. PMID: 37032440
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, Pinto Correia A, Natalie CR, Rodriguez Capriles C, Pierce E, Reifeis S, Gontijo Lima R, Armengol Tubau C, Laquer V, Weidinger S. Paller AS, et al. Among authors: weidinger s. Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15. Dermatol Ther (Heidelb). 2023. PMID: 37318750 Free PMC article.
Skin care interventions in infants for preventing eczema and food allergy.
Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E, Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Axon E, Cork M, Cooke A, Van Vogt E, Schmitt J, Weidinger S, McClanahan D, Simpson E, Duley L, Askie LM, Williams HC, Boyle RJ. Kelleher MM, et al. Among authors: weidinger s. Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD013534. doi: 10.1002/14651858.CD013534.pub3. Cochrane Database Syst Rev. 2022. PMID: 36373988 Free PMC article. Review.
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
Beck LA, Bieber T, Weidinger S, Tauber M, Saeki H, Irvine AD, Eichenfield LF, Werfel T, Arlert P, Jiang L, Røpke M, Paller AS. Beck LA, et al. Among authors: weidinger s. J Am Acad Dermatol. 2023 Apr;88(4):816-823. doi: 10.1016/j.jaad.2022.11.047. Epub 2022 Dec 5. J Am Acad Dermatol. 2023. PMID: 36473633 Free article. Clinical Trial.
The Treat-to-Target Project in Atopic Dermatitis: One Year On.
De Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink A, Richard MA, Shumack S, Silvestre JF, Thyssen JP, Weidinger S. De Bruin-Weller M, et al. Among authors: weidinger s. Acta Derm Venereol. 2023 Apr 21;103:adv5382. doi: 10.2340/actadv.v103.5382. Acta Derm Venereol. 2023. PMID: 37083095 Free PMC article.
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B. Weidinger S, et al. Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240. Br J Dermatol. 2023. PMID: 37463508 Free article. Clinical Trial.
Genetic and Immunological Pathogenesis of Atopic Dermatitis.
Schuler CF 4th, Tsoi LC, Billi AC, Harms PW, Weidinger S, Gudjonsson JE. Schuler CF 4th, et al. Among authors: weidinger s. J Invest Dermatol. 2024 May;144(5):954-968. doi: 10.1016/j.jid.2023.10.019. Epub 2023 Dec 11. J Invest Dermatol. 2024. PMID: 38085213 Review.
387 results